5-Amino-1MQ is a small molecule enzyme inhibitor that boosts cellular metabolism and may promote fat loss. By blocking the fat-regulating enzyme NNMT, 5-Amino-1MQ increases NAD⁺ levels and energy expenditure in cells[1]. Early studies in mice show it can reduce body fat without suppressing appetite[2], suggesting a unique weight-loss mechanism. However, it remains an experimental research compound with no human trials yet[3].

Aliases/Synonyms	Family/Pathway	Sequence (AA)	Molecular Weight (Da)	CAS Number	Typical Diluent(s)	Example Concentration	Storage (lyophilized / reconstituted)
5-Amino-1-methylquinolinium (5-Amino-1MQ) iodide[4]	Small-molecule NNMT inhibitor	N/A (not a peptide)	~258 g/mol[5]	1839590-54-7[6]	DMSO or PBS[7]	1–10 mM stock[8]	−20°C / −80°C for long term[9]

What is 5-Amino-1MQ?

5-Amino-1MQ (full chemical name: 5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). NNMT is found mainly in fat tissue, where it regulates energy metabolism by consuming SAM (S-adenosylmethionine) and indirectly lowering cellular NAD⁺ levels[10]. When NNMT is overactive (as seen in obesity), it drains NAD⁺, slowing metabolism and promoting fat storage.

By blocking NNMT, 5-Amino-1MQ effectively restores higher NAD⁺ levels in cells, boosting metabolic activity and reducing fat accumulation[11]. It is not a hormone, peptide, or stimulant — it works purely by enzyme inhibition at a molecular level. Because it is chemically stable and orally active in animal models, researchers have explored it as a potential treatment for obesity and metabolic disease.

In summary, 5-Amino-1MQ’s core action is to inhibit NNMT → raise NAD⁺ → activate metabolism. This mechanism is distinct from other weight-loss agents (e.g. GLP-1 agonists like semaglutide), making it an interesting area of study for metabolic health researchers.

Mechanism of Action

5-Amino-1MQ works through a specific biochemical pathway:

• NNMT Inhibition: 5-Amino-1MQ binds to the active site of NNMT and blocks it from methylating nicotinamide (vitamin B3). NNMT normally uses SAM to convert nicotinamide into methylnicotinamide — a reaction that consumes both SAM and NAD⁺ precursors[12].
• NAD⁺ Elevation: With NNMT inhibited, more nicotinamide is available to be recycled into NAD⁺ via the salvage pathway. Higher NAD⁺ activates sirtuins (SIRT1, etc.) and other enzymes involved in fat burning[13].
• SAM Preservation: By not consuming SAM for nicotinamide methylation, more SAM is available for other methylation reactions (gene regulation, etc.), which may further affect metabolic gene expression[14].
• Adipocyte Metabolism: In fat cells specifically, NNMT inhibition was shown to suppress lipogenesis (fat synthesis) and promote lipolysis (fat breakdown). In cell studies, 5-Amino-1MQ reduced fat accumulation in adipocytes[15].
• Whole-body Effects (Animal Data): In obese mice, treatment with 5-Amino-1MQ reduced white adipose tissue mass, improved insulin sensitivity, and lowered blood glucose — without reducing food intake[16]. These effects suggest the compound raises metabolic rate rather than suppressing appetite.

This mechanism makes 5-Amino-1MQ fundamentally different from stimulants or appetite suppressants. It acts at the level of enzyme activity and cellular energy metabolism, not on the central nervous system (at least based on current data).

Research and Clinical Evidence

Research on 5-Amino-1MQ is at an early stage, with studies limited to cells and animals:

• Fat Loss and Body Composition (Mouse Study): A key 2021 study (published in Cell Chemical Biology) tested 5-Amino-1MQ in diet-induced obese mice. The treated mice showed significantly reduced body fat (white adipose mass), improved glucose tolerance, and better insulin sensitivity compared to controls — without eating less[17]. This is the primary in vivo evidence for its anti-obesity effects.
• Cell-Level Lipid Reduction: In vitro, 5-Amino-1MQ suppressed lipogenesis and reduced lipid droplet formation in human fat cell models[18]. These cell studies help confirm the mechanism but cannot replace human trials.
• Metabolic Improvements Beyond Weight: Animal data also showed improvements in markers like plasma triglycerides and HDL cholesterol, suggesting broader metabolic benefits beyond just fat mass[19].
• No Human Trials: As of now, no published human clinical trials exist for 5-Amino-1MQ. The compound has not been evaluated for safety, efficacy, or pharmacokinetics in humans in any peer-reviewed setting[20].

Bottom line on evidence: The animal data is promising and the mechanism is scientifically coherent, but translating this to human use is speculative at this stage. Researchers and clinicians emphasize that animal results frequently do not replicate in humans, especially for metabolic compounds.

Reported Benefits

Based on the available (preclinical) research, the theorized or observed benefits of 5-Amino-1MQ include:

• Increased Fat Loss Without Appetite Suppression — The most notable finding is fat reduction without changes in food intake in mice[21]. If replicated in humans, this would represent a distinct advantage over appetite-suppressing drugs.
• Improved Insulin Sensitivity / Blood Sugar Control — Animal studies show better glucose tolerance and insulin sensitivity with treatment[22], which could theoretically benefit those with insulin resistance or metabolic syndrome.
• NAD⁺ Boosting — By inhibiting NNMT, 5-Amino-1MQ increases cellular NAD⁺[23]. Higher NAD⁺ is associated with improved mitochondrial function and may have anti-aging implications (as explored in NMN/NR research).
• Improved Lipid Profile — Reductions in triglycerides and improvements in HDL were seen in animal data[24].
• No CNS Stimulation — Unlike stimulant-based fat burners, 5-Amino-1MQ does not appear to act on the central nervous system, which could make it better tolerated in terms of cardiovascular side effects (though human data is absent).

Important caveat: These “benefits” are derived from mouse studies and cell culture experiments. They have not been confirmed in humans. Any claims beyond the animal data are extrapolations.

Dosage and Administration

There is no established human dosage for 5-Amino-1MQ. What circulates in research communities is extrapolated from animal studies and vendor recommendations for in vitro/in vivo use:

Parameter	Research/Animal Context	Human Extrapolation (Speculative)
Dose range (animal)	~10–50 mg/kg in mice[25]	Not established; not directly scalable
Route	Oral or intraperitoneal in mice	Some vendors offer oral capsules for research
Frequency	Daily in animal studies	Unknown
Cycle length	Weeks in animal models	Unknown

Some research peptide vendors suggest human doses of 50–100 mg per day orally, but these figures are not based on clinical trials. Do not use vendor-suggested doses as medical guidance.

Reconstitution and Storage

For laboratory research use, 5-Amino-1MQ is typically provided as a powder or in solution:

• Solubility: Soluble in DMSO (at least 50 mg/mL) and can be diluted into aqueous buffers (e.g., PBS) for cell culture use[26].
• Stock Solutions: Typical lab concentrations are 1–10 mM stocks in DMSO, stored at −20°C.
• Storage (Powder): Store at −20°C, protected from light and moisture[27].
• Storage (Reconstituted/Solution): Use within a short period (days to weeks) at 4°C, or freeze at −80°C for longer storage. Avoid repeated freeze-thaw cycles.

After reconstitution, store at 4°C and use within 1–2 weeks, or aliquot and freeze at −80°C to preserve stability.

Side Effects and Safety

The safety profile of 5-Amino-1MQ in humans is unknown. No toxicology studies, pharmacokinetics data, or safety trials in humans have been published. The following is based on animal data and general pharmacological reasoning:

• Animal Tolerability: In the published mouse study, 5-Amino-1MQ appeared well-tolerated at the tested doses, with no reported organ toxicity[28]. However, mouse models do not reliably predict human safety.
• NNMT’s Broader Roles: NNMT is expressed in multiple tissues (liver, muscle, brain), and its inhibition could have unintended effects beyond fat tissue. NNMT has roles in cancer biology, neurological function, and immune regulation — so blocking it systemically may carry risks not yet studied[29].
• No Known Human Side Effects: Because no human trials exist, reported “side effects” from online forums are anecdotal and cannot be substantiated.
• Potential Theoretical Risks: Altering SAM and NAD⁺ metabolism could theoretically affect methylation patterns (epigenetics), liver function, and muscle metabolism. These are hypothetical concerns, not confirmed findings.

If you’re considering 5-Amino-1MQ, understand that you would be taking a compound with zero human safety data. This is a significant unknown risk.

Legal Status and Availability

5-Amino-1MQ occupies a legal gray area in most countries:

• United States: Not FDA-approved for any use. Not a scheduled controlled substance. Sold legally by research chemical vendors as a “research compound” — not for human use[30].
• Other Jurisdictions: Regulatory status varies. In some countries, any unapproved pharmacological compound may require a prescription or be prohibited.
• Sports/Anti-Doping: 5-Amino-1MQ is not currently on WADA’s prohibited list, but its status could change as research evolves.
• Availability: Available from several research peptide suppliers online, typically in capsule or powder form. Quality control across vendors is not standardized, and purity can vary.

Comparison to Similar Compounds

Compound	Mechanism	Human Data?	Primary Use
5-Amino-1MQ	NNMT inhibitor → ↑NAD⁺	No	Fat loss, metabolic research
NMN / NR	NAD⁺ precursor supplementation	Limited human trials	Longevity, energy metabolism
Semaglutide (Ozempic)	GLP-1 receptor agonist	Extensive (FDA-approved)	Type 2 diabetes, obesity
AOD-9604	GH fragment, lipolysis	Some Phase I/II data	Fat loss
Tesamorelin	GHRH analogue	Yes (FDA-approved for HIV lipodystrophy)	Visceral fat reduction

Compared to established weight-loss drugs, 5-Amino-1MQ has a much weaker evidence base but a mechanistically interesting profile. It is best understood as a research tool rather than a clinical therapeutic at this stage.

Frequently Asked Questions

Q: What are the side effects of 5-Amino-1MQ?
A: No human side effects are documented. Animal studies showed good tolerability, but the safety profile in humans is completely unknown. Use in humans is experimental and carries undefined risks.

Q: Does 5-Amino-1MQ work for weight loss?
A: In obese mice, yes — it reduced body fat without reducing food intake. In humans, we don’t know. No human trials have been conducted.

Q: How does 5-Amino-1MQ differ from NAD⁺ supplements like NMN?
A: NMN/NR are NAD⁺ precursors — they provide building blocks to make more NAD⁺. 5-Amino-1MQ works by blocking the enzyme that depletes NAD⁺ (NNMT), so it raises NAD⁺ through a different pathway. The two approaches could theoretically be complementary.

Q: Is 5-Amino-1MQ legal?
A: In the US, it is not scheduled or banned, but it is not FDA-approved. It is sold for research purposes only. Legality varies by country — check local regulations.

Q: What is the recommended dose of 5-Amino-1MQ?
A: There is no clinically validated human dose. Some vendors suggest 50–100 mg/day orally based on animal data extrapolation, but this has no clinical validation.

Q: Can 5-Amino-1MQ be stacked with other compounds?
A: Combinations have not been studied. Theoretically, it might be considered alongside NAD⁺ precursors, but any combination use in humans is uncharted territory with compounded unknown risks.

Disclaimer

This article is for educational and informational purposes only. 5-Amino-1MQ is an experimental research compound not approved for human use by the FDA or any equivalent regulatory body. It has not been evaluated in human clinical trials. Nothing in this article constitutes medical advice, and this content should not be used to guide any personal health or medical decisions. Always consult a qualified professional before considering any research compound.